Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13
DUBLIN, Ireland and BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical…
DUBLIN, Ireland and BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical…
DUBLIN, Ireland and BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical…
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics NV. (Nasdaq:…
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics NV. (Nasdaq:…
SYDNEY, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q)…
SYDNEY, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q)…
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic…
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic…
ROCKAWAY, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
ROCKAWAY, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
CARSON CITY, Nev., Sept. 07, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
CARSON CITY, Nev., Sept. 07, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the…
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the…
• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza…
• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza…
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or…
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or…
Interstitial Lung Disease Experts Present Forced Vital Capacity Results from ATLAS Study Seattle, Sept. 07,…
Interstitial Lung Disease Experts Present Forced Vital Capacity Results from ATLAS Study Seattle, Sept. 07,…